IDEAYA BiosciencesIDYA +4.12%54 PS Ratio is 14.98 as of Jul. 05, 2026, which is 33% below its 10-year median of 22.23. GuruFocus rates IDYA with a GF Score™ of 54/100 and a GF Value™ of $205.30 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 933 Biotechnology companies, IDEAYA Biosciences ranks worse than 59.7% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, IDEAYA Biosciences's share price is $37.66.
IDEAYA Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.51. Hence, IDEAYA Biosciences's PS Ratio for today is 14.98.
The historical rank and industry rank for IDEAYA Biosciences's PS Ratio or its related term are showing as below:
IDYA'
s PS Ratio Range Over the Past 10 Years
Min: 10.41 Med: 22.23 Max: 521.33
Current: 14.98
During the past 9 years, IDEAYA Biosciences's highest PS Ratio was 521.33. The lowest was 10.41. And the median was 22.23.
IDYA's PS Ratio is ranked worse than 59.7% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs IDYA: 14.98
IDEAYA Biosciences Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of IDEAYA Biosciences was 3042.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 26.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -5.70% per year.
During the past 9 years, IDEAYA Biosciences's highest 3-Year average Revenue per Share Growth Rate was 26.20% per year. The lowest was -52.30% per year. And the median was -19.80% per year.
Back to Basics: PS Ratio
IDEAYA Biosciences (NAS:IDYA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
IDEAYA Biosciences PS Ratio Related Terms
IDEAYA Biosciences PS Ratio Historical Data
* Premium members only.
The historical data trend for IDEAYA Biosciences's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, IDEAYA Biosciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEAYA Biosciences PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where IDEAYA Biosciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
IDEAYA Biosciences's Share Price of today is $37.66. IDEAYA Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.51.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
IDEAYA Biosciences (IDYA) has a PS Ratio of 14.98 as of Jul. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on IDEAYA Biosciences and its competitors. This is 33% below median its historical median of 22.23. Over the past decade, IDEAYA Biosciences' PS Ratio has ranged from 10.41 to 521.33. According to the industry distribution chart, IDEAYA Biosciences ranks #557 out of 933 companies in the Biotechnology industry, placing it in the top 59.7%.
Is IDEAYA Biosciences' PS Ratio too high?
IDEAYA Biosciences' current PS Ratio of 14.98 is 33% below median its 10-year median of 22.23. Over the past 10 years, this metric has ranged from a low of 10.41 to a high of 521.33. The Biotechnology industry median PS Ratio is 9.64. IDEAYA Biosciences' value of 14.98 is 55.4% above this industry median. Based on the distribution chart, IDEAYA Biosciences ranks #557 out of 933 companies in the Biotechnology industry, which is below the industry midpoint. Overall, IDEAYA Biosciences has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IDEAYA Biosciences' PS Ratio compare to PBLS and ELVN?
According to the Biotechnology industry distribution chart, IDEAYA Biosciences ranks #557 out of 933 companies for PS Ratio. This places IDEAYA Biosciences in the lower half of its industry. The industry median PS Ratio is 9.64. IDEAYA Biosciences' value of 14.98 is 55.4% above this benchmark. Historically, IDEAYA Biosciences' own PS Ratio has ranged from 10.41 to 521.33 over the past decade. While the company's 10-year median is 22.23 vs. the industry median of 9.64, IDEAYA Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEAYA Biosciences's current PS Ratio of 14.98 is 55.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on IDEAYA Biosciences and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEAYA Biosciences's current PS Ratio is 14.98, which is 33% below median its own 10-year median of 22.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEAYA Biosciences stock overvalued right now?
Based on GuruFocus' analysis, IDEAYA Biosciences (IDYA) is currently considered Possible Value Trap. The stock's GF Value™ is $205.30, compared to a current price of $37.66 — trading 81.7% below its estimated fair value. The current PS Ratio is 14.98, which is 33% below median its 10-year median of 22.23 and 55.4% above the Biotechnology industry median of 9.64. IDEAYA Biosciences' overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For IDEAYA Biosciences (IDYA), the current PS Ratio is 14.98 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEAYA Biosciences (IDYA) Overvalued in 2026?
Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued.
The current stock price of $37.66 is trading 81.7% below its estimated GF Value™ of $205.30.
GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.
Key valuation signals for IDYA:
PS Ratio: 14.98 (33% below median its 10-year median of 22.23)
GF Value™: $205.30 vs. price of $37.66 (81.7% below fair value)
Industry Position: 55.4% above the Biotechnology median (#557 of 933)
No single metric tells the full story. See the IDYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
54GF Score
Get the complete analysis for IDYA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDYA has been successfully added to your 
